Introduction
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+LBCL) is a rare subtype of lymphoma that was first described in 1997. (1) Approximately 50 cases have been reported to date,(2) with most cases (60%) following an aggressive clinical course.(3) In well-characterized cases, 3 genes have been reported as a fusion partner of ALK: clathrin (CLTC-ALK), (4) (5) (6) nucleophosmin (NPM-ALK), (7) (8) and SEC31A (SEC31A-ALK). (9) In this paper, we report a case of ALK+LBCL that harbored a novel ALK fusion partner, sequestosome1 (SQSTM1).
Design and Methods

Materials
Biopsied specimens were fixed in 20% neutralized formalin and embedded in paraffin for conventional histopathological examination. We extracted DNA and total RNA from the snap-frozen specimens and subsequently purified the samples. Written informed consent was obtained from the patient. The study was approved by the Institutional Review Board of the Japanese Foundation for Cancer Research.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was used. For antigen retrieval, we heated the slides for 40 min at 97°C in Target Retrieval Solution (pH 9.0; Dako), and subsequently detected the immune complexes with a dextran polymer reagent (EnVision+DAB system, Dako) and an AutoStainer instrument (Dako).
Isolation of ALK fusion cDNA
To obtain cDNA fragments corresponding to novel ALK fusion genes, we used an inverse reverse transcription-polymerase chain reaction (RT-PCR) method slightly modified from one previously reported.(10) Double-stranded cDNA was synthesized from 2 µg of total RNA with 1 pM of the primer ALKREVex22-23 (5′-TGGTTGAATTTGCTGATGATC-3′) and a cDNA Synthesis System (Roche), and was self-ligated by incubation overnight with T4 DNA ligase (TaKaRa Bio). We subjected the resulting circular cDNA to PCR (35 cycles of 94°C for 15 sec, 62°C for 30 sec, and 72°C for 1 min) with primers ALKREV3T (5′-CTGATGGAGGAGGTCTTGCC-3′) and ALKFWDex20-21 (5′-ATTCGGGGTCTGGGCCAT-3′) in a final volume of 20 µl. We subjected 1 µl of the 1:100 diluted reaction products to a second PCR step (the same settings as above), with primers ALKREV4T (5′-GGTTGTAGTCGGTCATGATGGTC-3′) and ALKFWDex21-22
(5′-AGTGGCTGTGAAGACGCTGC-3′) in a final volume of 20 µl. The resulting products were purified by gel extraction and directly sequenced in both directions with primers ALKFWDex20-21 and ALKREV4T.
The fusion point of SQSTM1-ALK cDNA was amplified by RT-PCR with primers SQSTM1 565F (5′-AAACACGGACACTTCGGGT-3′) and ALK3078RR
(5′-ATCCAGTTCGTCCTGTTCAGAGC-3′).
Full-length SQSTM1-ALK cDNA was obtained from the specimen by RT-PCR with primers SQSTM1v1-F90 (5′-CTCGCTATGGCGTCGCTCACCGTGAA-3′) and KA-W-cDNA-out-AS (5′-CCACGGTCTTAGGGATCCCAAGG-3′).
Fluorescence in situ hybridization (FISH)
We performed FISH analysis of the gene fusion for unstained slides (4 µm thick) with bacterial artificial chromosome (BAC) clone-derived DNA probes for ALK (RP11-984I21, RP11-62B19) and SQSTM1 (RP11-55M16).
Transformation assay for ALK fusion protein
We performed analysis of the transforming activity of SQSTM1-ALK as described previously.(11-13) Briefly, cDNA for SQSTM1-ALK was inserted into the retroviral expression plasmid pMXS. (14) The resulting plasmid and similar pMXS-based expression plasmids for EML4-ALK variant 1 or NPM-ALK were used to generate recombinant ecotropic retroviruses, which were then used to infect mouse 3T3 fibroblasts. We evaluated formation of transformed foci after culturing the cells for 14 days. We subcutaneously injected the same set of 3T3 cells into nu/nu mice and examined tumor formation after 20 days.
PCR for IGH gene rearrangement
Genomic PCR was used for amplification of the rearranged IGH gene using the primers FR2A 5′-TGG(A/G)TCCG(A/C)CAG(C/G)C(C/T)(C/T)CNGG-3′ and LJH 5′-ACCTGAGGAGACGGTGACC-3′. Several clones were sequenced after subcloning the PCR product into pGEM-T-Easy Vector (Promega).
Results and Discussion
Case presentation The patient was diagnosed as having ALK+LBCL and achieved complete remission after 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment.
Four months later, however, he relapsed.
Identification of SQSTM1-ALK
The 2 major ALK fusions in ALK+LBCL are CLTC-ALK and NPM-ALK, and they show a coarse granular cytoplasmic pattern and a nuclear and cytoplasmic pattern in anti-ALK immunohistochemistry, respectively. In the present case, anti-ALK immunohistochemistry showed a diffuse cytoplasmic staining pattern with ill-demarcated spots ( Figure 1D ), which was different from either of the former 2 patterns. Therefore, we carried out inverse RT-PCR to examine the presence of a novel fusion of ALK. We indeed isolated a cDNA containing the exon NPM has a nuclear transport signal, while SQSTM1 does not. Therefore, NPM-ALK shows a nuclear and cytoplasmic staining pattern while SQSTM1-ALK shows only a cytoplasmic staining pattern. ALK is a representative "promiscuous" molecule because of its various fusion partners.
The subcellular localization of ALK fusions depends on the fusion partners. The anti-ALK immunohistochemical staining pattern is, therefore, a simple and useful means to identify the possible partner in a tested case, and in fact, has prompted the identification of many ALK fusion partners, including the present case.
Transforming activities of SQSTM1-ALK
We generated a recombinant retrovirus encoding SQSTM1-ALK and used it to infect cultured 3T3 fibroblasts. Infection with the virus, but not with an empty virus, resulted in the formation of multiple transformed foci in vitro ( Figure 2C ). As control experiments for formation, EML4-ALK (variant 1) and NPM-ALK similarly produced transformed foci (data not shown).
The same 3T3 cells were injected into nude mice for an in vivo tumorigenicity assay. As In conclusion, we reported a novel ALK fusion, SQSTM1-ALK, and its oncogenicity.
ALK+LBCL is an aggressive lymphoma with poor prognosis;(3) ALK inhibitors are promising therapeutic agents for this condition. SQSTM1-ALK may be a rare fusion, but our data provide novel biological insights and may serve as a key to the accurate diagnosis of this rare lymphoma. 
